Phibro Animal Health (NASDAQ:PAHC - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.870-2.010 for the period, compared to the consensus EPS estimate of 1.710. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on PAHC. StockNews.com lowered Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Thursday. Morgan Stanley raised their target price on Phibro Animal Health from $20.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Tuesday, December 17th. Finally, Barclays increased their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an "underweight" rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $20.50.
Read Our Latest Analysis on PAHC
Phibro Animal Health Stock Down 3.6 %
Shares of PAHC traded down $0.89 during trading hours on Friday, hitting $23.69. The stock had a trading volume of 330,418 shares, compared to its average volume of 137,832. The firm has a 50 day simple moving average of $21.90 and a 200-day simple moving average of $21.68. Phibro Animal Health has a 1-year low of $10.03 and a 1-year high of $25.98. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.69. The firm has a market capitalization of $959.45 million, a P/E ratio of 49.35, a price-to-earnings-growth ratio of 0.53 and a beta of 0.52.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a return on equity of 25.35% and a net margin of 1.75%. Sell-side analysts predict that Phibro Animal Health will post 1.94 EPS for the current fiscal year.
Phibro Animal Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Wednesday, March 5th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 2.03%. The ex-dividend date is Wednesday, March 5th. Phibro Animal Health's payout ratio is presently 100.00%.
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Featured Articles
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
